Last reviewed · How we verify

Amidephrine — Competitive Intelligence Brief

Amidephrine (amidefrine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: amidefrine. Area: Neuroscience.

unknown amidefrine Adrenergic receptor alpha-1, Adrenergic receptor alpha-2 Neuroscience Live · refreshed every 30 min

Target snapshot

Amidephrine (amidefrine). Amidephrine works by stimulating the sympathetic nervous system, which can increase heart rate and blood pressure.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Amidephrine TARGET amidefrine unknown amidefrine Adrenergic receptor alpha-1, Adrenergic receptor alpha-2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (amidefrine class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Amidephrine — Competitive Intelligence Brief. https://druglandscape.com/ci/amidefrine. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing